

REVIEW

Time to focus on circulating nucleic acids for diagnosis and monitoring of gliomas: A systematic review of their role as biomarkers

Ana Belén Díaz Méndez¹ | Elisa Tremante¹ | Giulia Regazzo¹ | Sebastian Brandner^{2,3}  | Maria G. Rizzo¹ 

¹Department of Research, Advanced Diagnostics and Technological Innovation, Genomic and Epigenetic Unit, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy

²Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK

³Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK

Correspondence

Maria Giulia Rizzo and Giulia Regazzo, Department of Research, Advanced Diagnostics and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144-Rome, Italy.
Email: maria.rizzo@ifp.gov.it; giulia.regazzo@ifp.gov.it

Funding information

We acknowledge the financial support by EU Horizon 2020 Marie Skłodowska-Curie Actions -ITN-ETN AiPBAND Project under grant No. 764281 (MGR and SB). GR is a fellow of "Associazione Mia Neri Foundation" supported by "Cassa Sovvenzioni e Risparmio Dipendenti Banca d'Italia". ABDM is an AiPBAND (H2020-MSCA-ITN-2017) fellow. SB is also supported by the UK Department of Health's NIHR Biomedical Research Centre's funding scheme to University College London Hospitals NHS Foundation Trust

Abstract

Gliomas are diffusely growing tumours arising from progenitors within the central nervous system. They encompass a range of different molecular types and subtypes, many of which have a well-defined profile of driver mutations, copy number changes and DNA methylation patterns. A majority of gliomas will require surgical intervention to relieve raised intracranial pressure and reduce tumour burden. A proportion of tumours, however, are located in neurologically sensitive areas and a biopsy poses a significant risk of a deficit. A majority of gliomas recur after surgery, and monitoring tumour burden of the recurrence is currently achieved by imaging. However, most imaging modalities have limitations in assessing tumour burden and infiltration into adjacent brain, and sometimes imaging is unable to discriminate between tumour recurrence and pseudo-progression. Liquid biopsies, obtained from body fluids such as cerebrospinal fluid or blood, contain circulating nucleic acids or extracellular vesicles containing tumour-derived components. The studies for this systematic review were selected according to PRISMA criteria, and suggest that the detection of circulating tumour-derived nucleic acids holds great promises as biomarker to aid diagnosis and prognostication by monitoring tumour progression, and thus can be considered a pathway towards personalized medicine.

KEYWORDS

biomarkers, blood, circulating nucleic acids, CSF, glioma, liquid biopsy

INTRODUCTION

Gliomas are the most common intrinsic brain tumours and are thought to arise from progenitor cells in the central nervous system (CNS) [1]. There is a significant variability between and within different tumour types, and a proportion of gliomas, such as the malignant form glioblastoma multiforme (GBM), shows a significant degree of intratumoural heterogeneity [1, 2]. The discovery of significant driver mutations such as isocitrate dehydrogenase (IDH) in 2008, BRAF or histone K27M has fundamentally changed the diagnostic approach in neuropathology [3–5]. This biomarker-driven classification is reflected in the 2016 update of the World Health Organization (WHO) classification of CNS tumours. This has resulted in the concept of an integrated diagnosis, combining histological diagnosis and molecular profile [6–8]. The diagnostic approach starts with the histological examination, followed by immunohistochemical stains and subsequent genetic or epigenetic analysis, to determine a mutation defining a tumour type or even to establish a methylation class [6, 9]. This diagnostic workup requires tumour material, for example, a brain biopsy, which can be limited (e.g. stereotactic needle biopsies), but can also be extensive after a debulking. After surgery, disease is monitored by magnetic resonance imaging (MRI). In patients with adjuvant radio- and chemotherapy, it may be difficult to reliably discriminate tumour progression from radiation necrosis [10]. While tissue biopsies are essential to establish a diagnosis and a molecular profile, they will always represent a static snapshot in time, which cannot reflect changes in the mutational spectrum, microenvironment and heterogeneity during recurrence and progression. The discovery of nucleic acids derived from tumours circulating in body fluids has opened up significant potential for monitoring tumour recurrence, progression and potentially even preoperative diagnosis. The minimally invasive nature of blood sampling facilitates serial testing and the monitoring of dynamic changes during tumour therapy [10]. Liquid biopsy detects molecular contents such as proteins or cell-free nucleic acids (cfNAs) from tumours in body fluids, either as cell-free entities, attached to lipid or protein structures, or as the content of vesicles, such as exosomes. Several classes of cfNAs exist: DNA and different classes of RNA, such as protein-coding mRNA and non-coding RNAs, for example, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). Cell-free DNA (cfDNA) includes DNA released from cancer cells, bearing tumour-specific genetic alterations and referred to as circulating tumour DNA (ctDNA) [11–14]. Although most liquid biopsies are derived from blood samples, other biofluids, including cerebrospinal fluid (CSF), can be used [15]. CSF could play a particular role as a source of brain tumour-specific biomarkers, as it circulates in close contact with the CNS, and even if its collection requires a lumbar puncture, which is more invasive and fraught with more risks than taking a blood sample, is still considerably less invasive than a brain biopsy.

The role of the blood–brain barrier (BBB) in the context of biomarkers derived from brain tumours has been a matter of significant

debate. It is assumed that the release of circulating biomarkers requires crossing of the BBB, and it is hypothesized that the scarcity of circulating markers in CSF or blood is due to the BBB [16]. However, a majority of diffuse gliomas, in particular, GBM, almost invariably have a disrupted BBB, and a more generous release of circulating biomarkers would be expected [10].

This review aims to discuss and summarize the current literature on cfNAs in blood and CSF of glioma patients. We focus on DNA and RNA (miRNAs and lncRNA) as a useful source of information that might complement the histopathological, molecular and imaging techniques, and on how they could be adopted into clinical practice for personalized medicine.

METHODS

Literature search strategy

A systematic literature search was performed following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines in three databases (PubMed, EMBASE and CENTRAL) from January 2000 to March 2020. A search strategy, limited to Title/Abstract, was defined. We used a combination of keywords and Boolean operators for the following key concepts: “circulating microRNAs”, “circulating tumour DNA”, “cell-free nucleic acids”, “glioma” and “liquid biopsy”. Details of the search strategy in the Data S1.

Eligibility criteria


Three co-authors (ABDM, ET and GR) independently screened titles, abstracts and full-text articles according to the following inclusion criteria: (1) full articles in English; (2) articles concerning the analysis of cfNAs in human blood and CSF from glioma patients and (3) studies evaluating nucleic acids as biomarkers. Case reports and review articles were excluded but their bibliography was screened to identify further articles that may have been missed with the search strategy.

RESULTS

Selected studies

After full-text screening, 89 articles were included (Figure 1A). One relevant study lacking our keywords and published after completion of the screening was added [17]. All the eligible studies were assessed for quality by the QUADAS-2 tool [18] (Data S1) and passed the criteria (Figure S1). The highest risk to the quality arose from the index test due to a high variance between the technical methods and normalizers between different studies. Articles regarding circulating miRNAs were homogeneous in terms of the methodology used for

FIGURE 1 Selection of studies by search strategy. (A) Flow diagram of the study selection process. (B) Schematic representation of selected articles on glioma cfNAs



detection. Instead, articles about cfDNA were mostly heterogeneous in terms of study design and methodology, rendering them less comparable.

Among the selected citations, 64 articles focused on the analysis of either cell-free RNA (cfRNA) as a single species, or exosomal RNAs (Table 1; Figure 1B), comprising mainly miRNAs [15, 19–71] and lncRNAs [72–78], and only few other RNA species [27, 79–81]. The other 25 articles discussed cfDNA [82–106] (Table 2; Figure 1B). Articles describing the prognostic impact of cfNAs were selected only if they included Progression-Free Survival (PFS), Disease-Free Survival (DFS) and/or Overall Survival (OS).

Circulating RNAs in the context of gliomas

The majority of the selected studies on cfRNA evaluated miRNAs, small non-coding RNAs considered potential circulating biomarkers [15, 19–71]. In contrast, only few articles evaluated other RNAs species [27, 72–81] such as non-coding single-stranded RNAs longer than 200 bp (lncRNAs) with important roles in multiple cellular functions [72–78]. However, most of the cfRNAs were described in blood [19, 21–23, 25–37, 39–42, 44–54, 56–81] and only a few articles focused on CSF [15, 20, 24, 34, 35, 43, 55]. The majority of cfRNA studies were done on patients with GBM (46%), followed by those with diffuse and anaplastic astrocytoma (12% each), while 15% of the articles did not specify the glioma subtype (Figure S2).

Cell-free RNAs in blood

Of the 46 publications about circulating miRNAs in plasma or serum, 45 described deregulation of miRNAs in glioma patients and compared them to either healthy individuals or patients with pathologies other than gliomas [19, 21–23, 25–33, 36, 37, 39–42, 44, 45, 47–54, 57–71]. This suggests their potential as diagnostic biomarkers (Table 1). Across these studies, 82 miRNAs were evaluated but only 12 were analysed in samples with homogeneous clinical features and were consistently deregulated [19, 21–23, 26, 28–30, 33, 36, 37, 40, 42, 47, 48, 50, 54, 58, 63, 68–70] (Figure 2A). Among these,

miR-21 was the most commonly investigated biomarker [19, 21, 22, 36, 37, 48, 68] and was one of the first miRNAs to be identified as an oncomiR in cancer, including gliomas [21]. miR-21 was upregulated in glioma patients and correlated with higher grades [19, 21, 22, 36, 37, 48, 68]. Another relevant miRNA is miR-497, downregulated not only in glioma tissues and cell lines [104] but also in serum [23, 41], and has been reported to correlate with tumour malignancy and to discriminate gliomas from other brain tumours [41].

Several studies explored the correlation of circulating miRNAs with the histopathological grade of glioma [22, 23, 28, 30, 32, 33, 35, 39, 41, 42, 44, 45, 47, 49, 52, 56, 63, 64, 66, 69]. However, this approach is fraught with inaccuracies, as it is increasingly recognized that the histological grade may not always accurately reflect the biological behaviour [6]. Yet, only few studies took the opportunity to integrate the molecular profile of gliomas with circulating miRNA levels [54, 61, 62, 67] (Figure 3). Most of them just evaluated the correlation between *IDH* status and the miRNAs of interest [61, 62, 67]. In the study of Ebrahimkhani et al. [54], a 13-miRNA signature was found to differentiate patients based on *IDH* mutational status with an estimated predictive power of 77.4%, demonstrating the potential of miRNAs for glioma molecular subtyping. Although these studies were performed to provide a diagnostic tool, they may also serve the purpose of identifying the prognostic and predictive value of miRNAs [21–23, 25, 26, 28, 29, 32, 35, 37, 39, 40, 46, 48, 49, 51–53, 56, 57, 59–64, 66, 67] (Table 1).

Overall, 28 circulating miRNAs have been proposed as prognostic biomarkers (Table 1). However, only miR-221, -222, -210, -106a and -145 were considered in more than one article and were reported as consistently dysregulated [26, 28, 29, 42, 52, 67, 70]. Levels of miR-221, miR-222 [26, 42, 52], miR-210 [29, 70] and miR-106a [28, 46] correlate with poorer PFS, OS or 2-year DFS. miR-210 and miR-106a are associated with tumour hypoxia and invasiveness and thus are considered oncomiRs in gliomas [28, 29]. In contrast, miR-145 levels are inversely correlated with OS [46, 67] and 2-year DFS [46]. This miRNA has also been evaluated as serum diagnostic marker but with inconsistent results [47, 67].

Table 1 shows miRNAs that have been identified as potentially useful biomarkers to predict treatment response. miR-128 increases post-operatively and during chemo-radiation therapy, and is the only

TABLE 1 Studies on circulating RNAs as non-invasive biomarkers in glioma based on our analysis

Reference	Biomarker	Detection method	Case size	Biofluid	Total or exosomal	Reason of interest
15	miR-21 miR-15b	Real-time PCR	10 gliomas vs. 40 controls	CSF	Total	Diagnostic
20	miR-10b miR-21	Real-time PCR	19 GBM vs. 74 metastasis and 15 controls	CSF	Total	Diagnostic, monitoring
79	mRNA (IDH1)	BEAMing and digital PCR	24 gliomas vs. 6 controls	CSF	EV	Detection
24	miR-21	Real-time PCR	28 GBM vs. 28 controls	CSF	Exosomal	Diagnostic
38	miR-451 miR-711 miR-935 miR-223 miR-125b	Real-time PCR	13 gliomas vs. 14 controls	CSF	Total	Diagnostic
55	miR-30e miR-140 let-7b miR-10a miR-21-3p miR-10b miR-196b	Sequencing and real-time PCR	175 brain tumours vs. 40 controls	CSF	Total	Diagnostic, prognostic
43	miR-548c miR-520f miR-27b miR-130b miR-21 miR-218 miR-193b miR-331 miR-374a	Microarray and real-time PCR	105 GBM and 90 controls	CSF	Exosomal and total	Diagnostic
81	mRNA (EGFRvIII)	Sequencing	71 gliomas	CSF	Exosomal	Detection
35	mir-21	Real-time PCR	70 gliomas vs. 25 controls	CSF and serum	Exosomal	Diagnostic, monitoring
80	mRNA (EGFRvIII)	Sequencing	13 gliomas vs. 6 controls	Blood	EV	Detection
19	miR-21	Real-time PCR	25 GBM vs. 30 controls	Serum	Exosomal	Diagnostic
23	miR-15b* miR-23a miR-133a miR-150* miR-197 miR-497 miR-548b-5p	Solexa sequencing and real-time PCR	123 gliomas vs. 127 controls	Serum	Total	Diagnostic, monitoring
27	mir-320 miR-574-3p RNU6-1	Microarray and real-time PCR	75 GBM vs. 55 controls	Serum	Exosomal	Diagnostic
44	miR-125b	Real-time PCR and meta-analysis	33 gliomas vs. 33 controls	Serum	Total	Diagnostic

(Continues)

TABLE 1 (Continued)

Reference	Biomarker	Detection method	Case size	Biofluid	Total or exosomal	Reason of interest
28	miR-15b-5p miR-16-5p miR-19a-3p miR-19b-3p miR-20a-5p miR-106a-5p miR-130a-3p miR-181-5p miR-208a-3p	Microarray and real-time PCR	150 gliomas vs. 160 controls	Serum	Total	Diagnostic, prognostic, monitoring
29	miR-210	Real-time PCR	136 GBM vs. 50 controls	Serum	Total	Diagnostic, prognostic
30	mir-128	Real-time PCR	151 gliomas vs. 105 controls	Serum	Total	Diagnostic, monitoring
45	miR-205	Real-time PCR	83 gliomas vs. 55 controls	Serum	Total	Diagnostic, prognostic, monitoring
70	miR-210	Real-time PCR	91 gliomas vs. 50 controls	Serum	Exosomal	Diagnostic, prognostic, monitoring
42	miR-451a	Real-time PCR	118 gliomas vs. 84 controls	Serum	Total	Diagnostic
31	miR-29a miR-29b miR-29c	Real-time PCR	83 gliomas vs. 69 controls	Serum	Total	Diagnostic
46	miR-145-5p miR-222-3p miR-182 miR-20a-5p miR-106a-5p	NanoString and real-time PCR	106 GBM	Serum	Total	Prognostic
61	miR-29b	Real-time PCR	177 gliomas vs. 80 controls	Serum	Exosomal	Diagnostic, prognostic, monitoring
67	miR-145-5p	Real-time PCR	169 gliomas vs. 50 controls	Serum	Total	Diagnostic, prognostic
64	miR-769-3p	Real-time PCR	113 gliomas vs. 95 controls	Serum	Total	Diagnostic, monitoring
65	miR-4763-3p miR-1915-3p miR-3679-5p	Microarray	170 gliomas vs. 410 controls	Serum	Total	Diagnostic
66	miR-34a	Real-time PCR	82 gliomas vs. 42 controls	Serum	Total	Diagnostic, prognostic
63	miR-214	Real-time PCR	100 gliomas vs. 100 controls	Serum	Total	Diagnostic, prognostic, monitoring
62	mir-100	Real-time PCR	95 GBM vs. 60 controls	Serum	Total	Diagnostic, prognostic, monitoring
68	miR-26a miR-21	Real-time PCR	15 gliomas vs. 11 controls	Serum	Total	Diagnostic, monitoring

(Continues)

TABLE 1 (Continued)

Reference	Biomarker	Detection method	Case size	Biofluid	Total or exosomal	Reason of interest
47	miR-1303 miR-130a miR-145 miR-335	Real-time PCR	9 paediatric gliomas vs. 3 controls	Serum	Total	Diagnostic
48	miR-21 miR-222 miR-124-3p	Real-time PCR	100 gliomas vs. 41 controls	Serum	Exosomal	Diagnostic, monitoring
49	miR-203	Real-time PCR	100 gliomas vs. 30 controls	Serum	Total	Diagnostic, prognostic
50	miR-451a miR-4298 miR-485-3p	Microarray and real-time PCR	36 GBM vs. 12 controls	Serum	Total	Diagnostic, prognostic
51	miR-1825	Real-time PCR	57 gliomas vs. 57 controls	Serum	Total	Diagnostic, prognostic
52	miR-376a miR-376b miR-376c	Real-time PCR	100 gliomas vs. 50 controls	Serum	Total	Diagnostic, prognostic
39	miR-137	Real-time PCR	64 gliomas vs. 64 controls	Serum	Total	Diagnostic, prognostic, monitoring
41	miR-497 miR-125b	Real-time PCR	22 gliomas vs. 8 meningiomas vs. 15 controls	Serum	Total	Diagnostic
36	miR-15b miR-21	Real-time PCR	30 gliomas vs. 82 controls	Serum	Total	Diagnostic
37	miR-10b miR-21	Real-time PCR	28 gliomas vs. 10 controls	Serum	total	Diagnostic, monitoring
56	miR-193b	Real-time PCR	122 gliomas vs. 68 controls	Serum	Total	Diagnostic, prognostic, monitoring
57	miR-365	Real-time PCR	31 GBM ^a	Serum	Total	Diagnostic
58	miR-221 miR-222	Real-time PCR	20 GBM vs. 20 controls	Serum	Total	Diagnostic, prognostic, monitoring
59	miR-1238	Real-time PCR	13 gliomas vs. 13 controls	Serum	Exosomal	Diagnostic, monitoring
76	LINK-A	Real-time PCR	52 gliomas vs. 38 controls	Serum	Total	Diagnostic
74	HOTAIR GAS5	Real-time PCR	106 GBM	Serum	Total	Prognostic
77	GASL1	Real-time PCR	62 gliomas vs. 52 controls	Serum	Total	Diagnostic, prognostic, monitoring
78	SBF2-AS1	Real-time PCR	20 GBM	Serum	Exosomal	Diagnostic, prognostic
75	HOTAIR	Real-time PCR	43 GBM vs. 40 controls	Serum	Exosomal	Diagnostic, prognostic
73	TUSC7	Real-time PCR	206 gliomas	Serum	Total	Prognostic
72	miR210HG	Real-time PCR	42 gliomas vs. 10 controls	Serum	Total	Diagnostic

(Continues)

TABLE 1 (Continued)

Reference	Biomarker	Detection method	Case size	Biofluid	Total or exosomal	Reason of interest
21	miR-21	Real-time PCR	10 GBM vs. 10 controls	Plasma	Total	Diagnostic and monitoring
22	miR-21 mir-128 miR-342-3p	Real-time PCR	50 gliomas vs. 10 controls	Plasma	Total	Diagnostic and monitoring
32	mir-454-3p	Real-time PCR	70 glioma vs. 70 controls	Plasma	Total	Diagnostic, prognostic, monitoring
25	miR-576-5p miR-340 miR-626 mir-320 miR-7-5p let-7g-5p	Microarray	3 GBM and 3 controls	Plasma	Total	Diagnostic
26	miR-221 miR-222	Real-time PCR and meta-analysis	50 gliomas vs. 51 controls	Plasma	Total	Diagnostic, prognostic
34	miR-21 miR-24 miR-125	Real-time PCR	9 GBM	CSF and plasma	Exosomal	Detection
33	mir-185	Real-time PCR	66 gliomas vs. 77 controls	Plasma	Total	Diagnostic, prognostic
69	miR-210 miR-185 miR-449 miR-5194	Real-time PCR	50 gliomas vs. 15 controls	Plasma	Exosomal	Diagnostic
71	miR-124	Real-time PCR	64 gliomas vs. 40 controls	Plasma	Total	Diagnostic, prognostic
54	miR-182-5p miR-328-3p miR-339-5p miR-340-5p miR-485-3p miR-486-5p miR-543 miR-144-5p miR-134-5p miR-493-3p miR-433-3p miR-382-5p miR-379-5p miR-370-3p miR-127-3p miR-381-3p miR-409-3p	Sequencing	26 gliomas vs. 35 controls	Plasma	Exosomal	Diagnostic
53	miR-122	Real-time PCR	74 gliomas vs. 74 controls	Plasma	Total	Diagnostic, prognostic

(Continues)

TABLE 1 (Continued)

Reference	Biomarker	Detection method	Case size	Biofluid	Total or exosomal	Reason of interest
40	mir-182	Real-time PCR	112 gliomas vs. 54 controls	Plasma	Total	Diagnostic, prognostic
60	miR-449a	Real-time PCR	30 gliomas vs. 12 controls	Plasma	Total	Diagnostic

^aNo information about controls.

biomarker reported in more than one article with consistent results [22, 30]. Other circulating miRNAs responded to recurrence [45, 59, 70] and/or therapy response [22, 37, 59] and were considered as non-invasive predictive biomarkers. For example, deregulation of miR-205 [45] or miR-1238 [59] in serum is related to GBM recurrence and temozolomide (TMZ) resistance. miR-21 was downregulated after surgery and chemo-radiation [22] and upregulated after treatment with bevacizumab [37]. At present, however, these data are either supported by a single study only, or are discrepant between studies, questioning the reliability of these miRNAs as biomarkers.

Seven studies reported on cell-free lncRNAs [72–78] (Figure 1A). In these articles, the lncRNAs LINK-A, HOTAIR, GAS5, GASL1, SBF2-AS1, TUSC7 and MIR210HG were considered as potential diagnostic, prognostic or monitoring markers (Table 1). However, among them, only HOTAIR, a well-characterized *trans*-acting lncRNA involved in the genome-wide reprogramming of chromatin in glioma [75], was evaluated as biomarker in more than one study [74, 75]. Tan and colleagues found HOTAIR elevated in both, total serum and in the exosome-enriched serum fraction from GBM patients, and its reduction 2 weeks after surgery [75]. Increased HOTAIR levels were associated with poorer survival [75]. A single report shows deregulation of LINK-A, GASL1, GAS5, TUSL7 and MIR210HG in the serum of glioma patients, with varied correlations with prognosis [72–74, 76–78]. Specifically, higher levels of LINK-A and MIR210HG are found in glioma patients and overexpression of GAS5 correlated with poorer outcome [72, 76]. Conversely, GASL1 and TUSL7 are downregulated in patients and this correlates with poorer prognosis [73, 77]. Moreover, only MIR210HG and TUSL7 also correlated with glioma malignancy grade [72, 73] (Figure 3). SBF2-AS1 is the only lncRNA studied in relation to treatment response and is studied in the exosome-enriched fraction [78].

Cell-free RNAs in CSF

Even though the number of studies on cfRNAs in CSF is much smaller than those on blood, we still consider them highly relevant (Figure 2A). Three articles comparing miRNA levels both in CSF and blood are particularly significant [24, 34, 35]. Shi et al. showed that miR-21 in CSF, but not in serum, can discriminate GBM patients from healthy subjects [35], and another study confirms deregulation in CSF but not in plasma of GBM patients compared with healthy individuals [34]. While CSF contains fewer miRNAs than plasma or serum, it is arguably a more relevant source for brain tumour

biomarkers, as blood may contain miRNAs from a broader range of sources and may be more susceptible to “contamination” with hematopoietic cells, potentially hindering detection of relevant miRNAs [34, 55]. As previously mentioned, only miR-21 was reported in multiple studies [15, 20, 24, 35, 43], found to be upregulated in correlation with glioma grade [35, 48], and it has been evaluated as predictive marker [20, 55] or to monitor treatment response [20, 35], suggesting that CSF miR-21 is potentially a reliable biomarker for disease monitoring and management, including the assessment of relapses, remissions or efficacy of chemo-radiotherapy [20, 35]. For example, evaluation of miR-21 levels showed an increase in a patient 25 weeks post-radiation, correlating with disease progression seen on MRI, PET-CT and confirmed by tissue biopsy [20]. Other CSF markers, evaluated in single studies only, are miR-15b, miR-10b and miR-193b, were reported as consistently deregulated also in blood [15, 20, 28, 36, 37, 43, 56].

Circulating DNA in glioma patients

These studies, based on the detection of genetic and epigenetic alterations in cfDNA isolated from blood and CSF (Table 2), evaluated several genetic alterations as candidate biomarkers including *IDH1* mutation [87–106], copy number variations (CNVs), such as loss of heterozygosity for 1p, 10q, 19q [93, 100], gain in chromosome 7 and loss of chromosome 10 [101], EGFRvIII mutation [91] and abnormal methylation of *MGMT*, *p16*, *DAPK*, *RASSF1A*, *p73*, *RARBeta*, *PTEN*, *p15INK4B* and *p14ARF* promoters [82–84] (Figure 1B).

Cell-free DNA in blood

The selected studies on cfDNA in blood comprise studies in plasma [83, 86, 91, 92] and serum [82, 84, 86, 89, 90, 96, 99] (Figure 2B). Most of the studies had as a main objective the analysis of the methylation status of gene promoters or of repetitive elements, such as Alu sequences, the most abundant families of repetitive elements of the human genome, frequently hypomethylated in cancer [82, 84, 85, 89, 90, 96, 99, 105]. Evidence of a correlation between DNA methylation in glioma tumour samples and in serum ctDNA was provided, for the first time, by Balaña and colleagues [82] who evaluated promoter methylation of *MGMT*, *p16*, *DAPK* and *RASSF1A* and showed a correlation between *MGMT* methylation and response to treatment and PFS, in tissue and in serum.

TABLE 2 Studies on circulating DNA as non-invasive biomarker in glioma based on our analysis

Reference	Biomarker	Detection method	Case size	Biofluid	Total or exosomal	Reason of interest
95	A panel of cancer-associated genes (most relevant <i>TERT</i> promoter, <i>TP53</i> , <i>IDH1</i> , <i>NF2</i> , <i>PIK3R1</i> , <i>PTCH1</i> , <i>PTEN</i>)	Sequencing	29 gliomas vs. 6 medulloblastomas	CSF	Total	Diagnostic
97	341 cancer-associated genes (most relevant <i>CD4K AMP</i> , <i>IDH1R132H</i> , <i>1p/19q del</i> , <i>PDGFRA AMP</i> , <i>CDKN2B</i> , <i>EML4-ALK</i> gene fusion)	MSK-IMPACT	12 gliomas	CSF	Total	Diagnostic
104	410 cancer-associated genes (most relevant <i>EGFR</i> , <i>CDKN2A/CDKN2B</i> , <i>EGFR</i> -variant III, <i>1p/19q</i> codeletion, <i>TERT</i> promoter, <i>TP53</i> , <i>IDH1</i>)	Sequencing	85 gliomas	CFS	Total	Diagnostic, monitoring
103	<i>IDH1</i> , <i>IDH2</i> , <i>TP53</i> , <i>TERT</i> , <i>ATRX</i> , <i>H3F3A</i> , <i>HIST1H3B</i>	Sequencing	20 gliomas	CFS	Total	Diagnostic
101	Mutation, copy number alteration (most relevant <i>IDH1</i> , <i>IDH2</i> , <i>TP53</i> , <i>CDKN2A/CDKN2B</i> , <i>EGFR</i>)	Whole-genome sequencing	13 gliomas	CSF	Total	Diagnostic
82	<i>MGMT</i> , <i>P16</i> , <i>DAPK</i> , <i>RASSF1A</i>	MSP	28 GBM	Serum	Total	Monitoring
85	<i>MGMT</i> , <i>PTEN</i> , <i>10q</i> , <i>1p/19q</i>	MSP and real time PCR	70 gliomas vs. 20 controls	Serum	Total	Prognostic
84	<i>p16</i>	MSP	40 gliomas	Serum	Total	Diagnostic
99	<i>ALU</i> , <i>MGMT</i> , <i>P16</i> , <i>RASSF1A</i>	MSP	124 gliomas vs. 58 controls	Serum	Total	Diagnostic, prognostic
90	<i>ALU</i>	BSP	65 gliomas vs. 30 controls	Serum	Total	Diagnostic, prognostic
89	<i>RASSF1A</i> , <i>p15INK4B</i> , <i>MGMT</i> , <i>p14ARF</i>	MSP	17 gliomas	Serum	Total	Diagnostic
83	<i>p16</i> / <i>INK4a</i>), <i>MGMT</i> , <i>P73</i> , <i>RARBeta</i>	MSP	10 gliomas	Plasma	Total	Monitoring
87	<i>IDH1</i>	COLD PCR and digital PCR	80 gliomas vs. 31 controls	Plasma	Total	Diagnostic
92	<i>MGMT</i> methylation	Real time PCR	58 gliomas	Plasma	Total	Monitoring
91	<i>EGFRvIII</i>	Long range PCR amplification	13 GBM	Plasma	Total	Monitoring
105	Panels of cancer-associated gene (most relevant <i>IDH1</i> , <i>TERT</i> , <i>CDKN2A/CDKN2B</i> , <i>EGFR</i> , <i>P53</i> , <i>PTEN</i> , <i>NTRK</i> fusion)	NGS	419 primary brain tumours	Plasma	Total	Monitoring
96	<i>ALU</i>	BSP	109 gliomas	Serum	Total	Diagnostic, prognostic
106	Panel of cancer-associated gene (most relevant <i>IDH1</i> , <i>MGMT</i> , <i>TP53</i> , <i>EGFRvIII</i> , <i>NF1</i> , <i>PTPN11</i> , <i>PDGFRA</i> , <i>PIK3CA</i> , <i>STAG2</i>)	NGS	42 gliomas	Plasma	Total	Prognostic
86	<i>MGMT</i> , <i>p16INK4a</i> , <i>TIMP-3</i> , <i>THBS1</i>	MeDIP (Methylated DNA Immunoprecipitation) and real-time PCR	86 gliomas	CSF and serum	Total	Prognostic, monitoring
88	<i>ALU</i>	Real time PCR	70 gliomas vs. 20 controls	CSF and serum	Total	Diagnostic

(Continues)

TABLE 2 (Continued)

Reference	Biomarker	Detection method	Case size	Biofluid	Total or exosomal	Reason of interest
93	MGMT	MSP	89 gliomas	CSF and serum	Total	Diagnostic, prognostic
94	PTEN, IDH1	Digital PCR	12 gliomas	CSF and plasma	Total	Diagnostic
98	H3K27M	Digital PCR	48 gliomas vs. 36 controls	CSF and serum	Total	Monitoring
102	Alteration in DNA	Sequencing	200 patients 65 controls	Plasma	Total	Diagnostic
100	Promoter TERT mutation	Real-time PCR and Ion Torrent PGM NGS system	60 gliomas	CSF and plasma	Total	Prognostic
17	DNA-methylation profiles	cfMeDIP-seq	220 patients	Plasma	Total	Diagnostic

BPS, Bisulfite sequencing PCR; MSP, Methylation-specific PCR.

These data were confirmed by two other studies [83, 85]. Lavon and collaborators [85] found that serum ctDNA in glioma patients is informative for both loss of heterozygosity and DNA methylation status during the course of the disease. The sensitivity was moderate due to false-negative samples depending on tumour size, but there was a specificity close to 100% for low- and high-grade tumours [86]. Another study on *MGMT* promoter methylation showed a high concordance between methylation levels in tumour tissue and plasma, and its correlation with longer survival, supporting the utility of the detection of *MGMT* promoter methylation in ctDNA for prediction of treatment response [92]. However, the authors highlighted that only methylated promoter status is specific, while the detection of an unmethylated *MGMT* promoter may represent a false-negative finding [92]. Three articles discussed the importance of hypomethylation of Alu sequences as biomarker in glioma [90, 94, 99]. Chen et al. [90] showed a statistically significant correlation between Alu methylation level in tumour and serum from all patients. Specifically, they demonstrated that Alu methylation in cfDNA was significantly lower in patients compared to healthy individuals. Surprisingly, Alu methylation levels in cfDNA were lower in patients who died from glioma than in those still alive or who died from other causes. These results indicate that Alu methylation levels may be prognostic in glioma, confirmed by subsequent studies [96].

Gong and colleagues [99] conducted a large study with 124 patients and 58 healthy individuals, and proposed that *MGMT* hypermethylation and Alu hypomethylation could serve as a novel diagnostic and prognostic marker in gliomas. In particular, they showed that Alu sequences were hypomethylated, and *MGMT* hypermethylated in glioma patients, and also p16 methylation levels were altered compared to controls. The methylation levels in tissue and serum correlated, thus supporting the potential use of ctDNA as early diagnostic/predictive biomarker for precision medicine in gliomas. Finally, four studies focused on specific mutations in blood ctDNA [87, 91, 105, 106]. EGFRvIII, a truncated constitutively active mutation in the EGF receptor (EGFR), present in a proportion of *IDH*-wild-type GBMs, was reliably detectable in ctDNA, the study was limited by a small sample size [91]. Bagley et al. [106] observed an association of plasma cfDNA levels with PFS and OS and a correlation with radiographic tumour burden, in a cohort of 42 GBM patients. By Next Generation Sequencing (NGS) analysis, they demonstrate the detection of tumour-specific mutations in the serum of 75% of the patients, suggesting that plasma cfDNA has a utility as non-invasive biomarker of tumour burden, prognosis and may also be a substrate for molecular profiling in association with tissue sequencing [106]. The efficient detection of tumour mutations in plasma ctDNA has also been demonstrated by Piccioni and colleagues [105], who found in a large cohort of brain tumour patients, including those with gliomas, at least one genetic alteration in 50% of patients, with higher proportions when assessing only patients with GBM [105].

Boisselier et al. [87] used a combination of COLD (co-amplification at lower denaturation temperature) PCR and digital PCR to

FIGURE 2 Circulating nucleic acids in blood and CSF. (A) Circulating miRNAs and lncRNAs; red: cfRNAs more reliable as biomarkers; (B) circulating DNA; red: methylation, blue: deletions, black: mutations





FIGURE 3 Circulating non-coding RNA correspond to glioma grade and molecular markers



detect the *IDH1* c.395G>A (encoding the *IDH1* p.R132H or *IDH1*^{R132H}) mutation in serum ctDNA. The required specificity of 100% was achieved with a sensitivity of 60% and correlated with the tumour volume measured on MRI [87]. In conclusion, these studies show a correlation of genetic and epigenetic alterations between tissues and blood ctDNA (Figure 2B). However, advancements in MRI techniques and MR spectroscopy which can predict IDH mutation and even 1p/19q codeletion [107] render this assay less useful than a few years ago.

Cell-free DNA in CSF

All studies selected for this review demonstrate the possibility to identify genomic alterations such as CNVs or mutations in CSF with high sensitivity, in many cases comparable to that of tissues or blood analyses, which is of interest for diagnosis and prognostication (Table 2).

Among the selected articles on circulating biomarkers in CSF [86, 88, 92, 94, 97, 98, 100], six reports compared cfDNA levels in both CSF and blood [86, 88, 93, 94, 98, 100] (Figure 2B).

One of the first studies on ctDNA in CSF was conducted by Liu et al. [86]. These authors used methylated DNA immunoprecipitation to detect gene promoter hypermethylation in *MGMT*, *p16INK4a*, *TIMP-3* and *THBS1* in tumour tissue, serum and CSF from glioma patients. They found a correlation between methylation levels and survival, concluding that the methylation status of these genes may become a promising prognostic factor and may serve as minimally invasive tumour marker. Pentasova et al. [97] explored DNA profiling by high-throughput sequencing of CSF to evaluate the possibility of

identifying tumour-associated mutations in patients with known or suspected brain tumours. Such alterations were detected in patients with tumours but not in healthy individuals, suggesting that characterization of ctDNA in CSF holds promises for disease monitoring [97].

Studies using DNA sequencing showed that target DNA was more readily detectable in CSF than in plasma [94, 100]. De Mattos-Arruda [94] showed that CSF ctDNA is more representative than plasma to detect genomic alterations of brain tumours (mutations and CNVs in *EGFR*, *PTEN*, *ESR1*, *IDH1*, *ERBB2* and *FGFR2*). Juratli et al. [100] conducted a pilot study to assess the feasibility and the potential implications of detecting *TERT* promoter mutations in ctDNA from CSF and plasma of GBM patients. Interestingly, this study, and that of Wang et al. [95], showed that the detection of mutations originating from tumour cells in the CSF was greatly facilitated if the tumour was high grade, and adjacent to CSF cisterns, while these markers were not detectable in patients with low-grade gliomas even if in contact with CSF, or when tumours were encapsulated within the brain or spinal cord, suggesting that the tumour location is an important contributing factor to the sensitivity of this assay [95, 100]. Martínez-Ricarte et al. [103] performed an analysis of seven genes (*IDH1*, *IDH2*, *TP53*, *TERT*, *ATRX*, *H3F3A* and *HIST1H3B*) on 20 tumour specimens and corresponding CSF samples, using a sequencing platform. They demonstrate that genomic analysis of gene mutations in CSF ctDNA allowed the correct classification of 79% of tumours according to the molecular subtype, which can significantly facilitate clinical management of the patients [103]. In a recent publication, Miller and colleagues [104] evaluated the representation of the tumour genome in the CSF of 85 glioma patients. Tumour-derived

DNA was detected in the CSF of nearly half of the patients and was associated with disease burden and adverse outcome. The genomic landscape of glioma in CSF demonstrated a broad spectrum of genetic alterations and closely resembled that in tumour samples, suggesting that ctDNA in the CSF may be an early indicator of progression [104]. It has yet to be established if the higher specificity of ctDNA in CSF outweighs the higher risks of lumbar puncture compared with the more accessible serum or plasma and it is conceivable that low-risk procedures may be prioritized (e.g. serum) and in case of non-informative results may be followed up by higher-risk interventions (e.g. CSF, brain biopsy).

Extracellular vesicles in glioma

Tumour-derived nucleic acids can be detected as cell-free entities or as the contents of circulating membrane-derived extracellular vesicles (EVs). These are ubiquitous in biofluids including blood and CSF. The most extensively characterized EV categories are microvesicles (200–500 nm diameter) and exosomes (40–100 nm diameter) [108]. Increased microvesicle content has been observed in plasma from glioma patients suggesting that EVs may represent an important source suitable for profiling of nucleic acids in gliomas [109].

The first record of exosomal non-coding RNA isolated from GBM patients was reported by Manterola and colleagues [27], who found that the expression levels of RNU6-1, miR-320 and miR-574-3p were significantly associated with a diagnosis of GBM. Exosomal miRNAs are involved in several important biological processes, including cell proliferation and resistance to apoptosis [27]. However, among all miRNAs evaluated, both in blood and CSF [19, 24, 27, 34, 41, 48, 54, 59, 61] (Table 1), only miR-21 and miR-210 may be considered sufficiently reliable markers, as they have been described in more than one study [41, 69, 88]. With respect to exosomal lncRNAs, only HOTAIR and SBF2-AS1 have been found as potential markers in our research strategy [75, 79]. Tan and colleagues [75] showed that HOTAIR is absent in exosome-depleted serum, suggesting that this lncRNA circulates mainly inside exosomes [75]. Exosomal SBF2-AS1, the only lncRNA studied in the context of chemotherapy response, is increased in GBM patients and associated with poor response to TMZ treatment [79]. However, the debate about the relative contribution of exosomal non-coding RNAs to whole serum/plasma RNA is still open. Although some authors have demonstrated that RNAs in blood exist primarily inside exosomes, where they are detectable at higher sensitivity [75], other studies claim that the majority of non-coding RNAs in blood is located primarily outside exosomes [110]. The reason for these discrepancies is unclear but may be ascribed, at least partly, to differences in isolating exosomes or differences between plasma and serum. Indeed, unlike in plasma, serum miRNAs were more commonly found in exosomes than freely circulating [111].

Other studies have demonstrated that circulating EVs may be a source of material to analyse tumour-specific mutations [19, 79, 80]. In particular, Chen et al. described a novel approach that combines

beads, emulsions, amplification, magnetics (BEAMing) RT-PCR and droplet digital PCR to identify glioma mutations. EVs from patient CSF were used to reliably detect and quantify mutant and wild-type IDH1 mRNA [79]. Moreover, RNA from EVs has been used to detect the EGFRvIII transcript in GBM patients [19, 80, 81]. In particular, in a multicentre study of 71 patients, Figueroa et al. demonstrated that CSF-derived EVs may allow the detection of EGFRvIII and *EGFR* amplification [81]. The current difficulties in isolating tumour-specific EVs remain a challenge and may limit their use in clinical settings. For these reasons, several methods have been proposed to isolate EVs from biofluids [79, 80]. A sensitive analytical microfluidic platform (EVHB-Chip) for tumour-specific EV-RNA isolation has achieved 94% tumour-EV specificity, has a detection limit of 100 EVs/ μ L and a 10-fold tumour RNA enrichment compared to other methods [80]. Testing serum/plasma samples of GBM patients with the EVHB-Chip, relatively rare EGFRvIII transcripts were identified, as well as genes expressed in specific GBM subtypes [80].

DISCUSSION

Gliomas represent a medical challenge due to their anatomical location, their diffuse and infiltrative growth, the resulting impact on brain functioning and their biological complexity [1]. The histological and molecular stratification of tumour types is based on multiple genetic and epigenetic characteristics of the tumour that have both diagnostic and prognostic value. In mainstream diagnostic pathology settings, these molecular markers are tested on histologically assessed, and thus validated, starting material. This approach can be limited when patients are at increased risk from a biopsy due to tumour location, clinical performance status or comorbidities [2]. Liquid biopsies, in contrast to tissue biopsies, have the potential to extend the diagnostic options for high-risk patients, by their minimally invasive approach, for example, allowing repeated sampling for disease monitoring. With continuous refinement of technological options, liquid biopsies can potentially assess a wide range of molecular markers, with high sensitivity and specificity. The results may in the future facilitate the clinical decision-making process, to balance the risk and benefits of surgical tumour removal. Initially, liquid biopsy studies focused on circulating tumour cells, but interest soon moved towards cfNAs, as they are easier to collect and analyse [11]. The discovery of cfNAs in the blood stream dates back to the detection in 1947 by Mandel and Metais, of DNA and RNA in the plasma of healthy and ill individuals [12, 112]. Forty years later, cancer-specific DNA mutations were found in the blood of cancer patients, suggesting the potential of ctDNA as a tumour biomarker [113]. In 2008, circulating miRNAs were reported for the first time in the serum of glioma patients [19]. cfDNA comprises small fragments of DNA (180–200 base pairs) released by cells under physiological and pathological conditions. It is suggested that the main source of cfDNA are apoptotic cells [114] although active secretion has also been proposed. When released by cells under physiological conditions, these fragments are generally cleared by phagocytosis, thus,

cfDNA levels are typically low in healthy individuals [13]. In tumours, the amount of cfDNA varies and is thought to reflect the burden of disease [11, 85]. cfDNA might carry tumour-specific mutations, as ctDNA, representing an important source of information about the tumour type [14]. Tumour cells can also release different classes of RNA, such as mRNA and non-coding RNAs. Among the latter, miRNAs are the most frequently investigated as biomarkers mainly due to their frequent alteration in cancer [115] and their high stability in biofluids [116, 117].

The studies reviewed here mostly focus on cfRNAs, in particular, non-coding RNAs. This category of transcripts is frequently deregulated in biofluids of glioma patients and, with a sensitivity in the range of ~30–99% and a specificity of ~70–100%, hold promise for disease detection [15, 22, 24, 26–33, 35, 36, 40–44, 52, 54–56, 61–65, 67, 70, 71, 75–77]. miR-21, consistently upregulated in patients biofluids, is one of the most investigated miRNAs, and is considered an oncomiR [21]. It is implicated in a variety of cellular and molecular pathways relevant in gliomagenesis [15]. miR-497, another candidate biomarker, is implicated in glioma cell growth and invasion through the Wnt3a/c-jun/miR-497 feedback axis and is associated with angiogenesis and TMZ resistance by targeting mTOR/Bcl-2 [118]. Some miRNAs correlate with patient outcome and can serve as prognostic/predictive biomarkers, [21–23, 25, 26, 32, 33, 35, 37, 39, 40, 42, 45, 46, 49–53, 56–64, 66–68, 70] with the most relevant ones belonging to the miR-221/222 family, which is involved in glioma cell invasion, proliferation and apoptosis, regulating multiple target genes [26]. However, the value of circulating miRNAs as prognostic marker or tool for monitoring tumour growth has been less explored, and in many studies miRNA levels were evaluated just before and after surgery [20, 22, 23, 28, 30, 39, 42, 45, 48, 61, 63, 68, 70] and not in relation to chemotherapy [22, 37, 59]. Despite the large number of cfRNA molecules examined, only few of them have yielded consistent results across different studies. This high variability limits their utility as non-invasive biomarkers and could be explained by differences in study design, sample size, ethnicity and methodology used [28]. Another limitation is the lack of an association of cfRNA to the molecular features of the tumours as, despite the 2016 update of the WHO classification, few articles have evaluated the correlations with molecular markers [54, 61, 62, 67].

There are fewer articles studying cfDNA [82–106] in gliomas than those on cfRNA [15, 19–81], but the high specificity (>80%) [85, 87, 89, 94, 96, 99, 100] in detecting tumour-derived cfDNA is compelling, rendering them potentially suitable for complementing molecular analysis of tumour biopsies, even if sensitivity levels can be highly variable (8–80%) depending on the biomarker evaluated and the biofluid analysed [85, 87, 89, 94, 96, 99, 100]. The small number of these studies can be explained by the difficulties in retrieving ctDNA from blood of patients with gliomas compared to other cancers [119].

The presence of BBB must be taken into account when considering cfNAs as brain tumour markers. The BBB integrity is often compromised in gliomas with different degrees of disruption in different

stages and grades. Changes in BBB permeability can be observed on MRI [16]. To investigate the influence of BBB on circulating biomarkers, Nabavizadeh and colleagues evaluated the relationship between MRI metrics, reflecting BBB disruption and plasma cfDNA concentration in GBM patients. They found that cfDNA concentration and tumour volume correlated only in patients with high degrees of BBB disruption. These data suggest that the reliability of cfDNA as a biomarker is dependent on the level of BBB permeability [119]. However, how aspects of the BBB impact on liquid biopsy is still unknown, thus more studies are required to address this issue. EVs as carriers of tumour-derived components are of great interest in liquid biopsies in glioma patients, as they can cross the BBB and are readily detectable in the plasma [120]. However, the evaluation of BBB permeability by MRI could be used as a complementary analysis with cfNAs evaluation to support their reliability as biomarkers in gliomas [16].

In conclusion, the studies discussed in this review demonstrate the increasing role and potential of cfNAs as biomarkers that can be obtained with minimal (blood) or moderate (CSF) invasiveness. With increasingly sensitive detection methods and continued validation, they may, at some point, become an additional diagnostic tool for detection of alterations that occur early during tumourigenesis and are specific for certain tumour types (e.g. *IDH* mutation, 1p/19q codeletion, *EGFR* amplification, *TERT* promoter mutation, histone mutation, etc.), which is useful for stratification of patients with certain glioma subtypes [81, 87, 91, 100, 103, 104, 106]. This might help with clinical trial stratification and genotype-directed therapies of these tumours. Moreover, cfNAs may be used for early identification and monitoring of relapses, for assessing therapy response of gliomas (e.g. monitoring changes in variant allele fraction of a given mutation) [20, 35, 59, 82, 99, 105] and potentially also discriminating progression from pseudo-progression, with the possibility of identifying subgroups of patients amenable of alternative therapeutic approaches [106]. The diagnostic implementation will now require a validated detection method in order to improve reliability and clinical utility of the analysis, agreement on the most suitable biomarkers and ideally prospective clinical biomarker trials. Clinical studies on cfNAs should adhere to REporting recommendations for tumour MARKer prognostic studies (REMARK) guidelines [121]. For the time being, multiple avenues need to be pursued to identify the most suitable methodologies, biomarkers and test indications.

ACKNOWLEDGMENTS

We thank Francesca Servoli and Virginia Scarinci (Scientific Library Knowledge Center “Riccardo Maceratini”, IRCCS Regina Elena National Cancer Institute – Rome, Italy) for the assistance in developing the search strategy across different databases.

CONFLICT OF INTEREST

The authors disclose no financial and personal relationships with other people or organizations that could inappropriately influence the article content.

AUTHORS CONTRIBUTIONS

ABDM: literature screening, manuscript preparation; ET: literature screening, manuscript preparation; GR: screening support, plan management, manuscript preparation; SB: manuscript revision; MGR: plan management, manuscript preparation. All authors read and approved the final manuscript.

PEER REVIEW

The peer review history for this article is available at <https://publons.com/publon/10.1111/nan.12691>.

DATA AVAILABILITY STATEMENT

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

ORCID

Sebastian Brandner  <https://orcid.org/0000-0002-9821-0342>

Maria G. Rizzo  <https://orcid.org/0000-0002-5009-2412>

REFERENCES

- McFaline-Figueroa JR, Lee EQ. Brain tumors. *Am J Med*. 2018;131:874-882.
- Molinari E, Curran OE, Grant R. Clinical importance of molecular markers of adult diffuse glioma. *Pract Neurol*. 2019;19:412-416.
- Capper D, Weissert S, Balsl J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. *Brain Pathol*. 2010;20:245-254.
- Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. *Acta Neuropathol*. 2011;122:11-19.
- Khuong-Quang DA, Buczkowicz P, Rakopoulos P, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. *Acta Neuropathol*. 2012;124:439-447.
- Louis DN, Wesseling P, Aldape K, et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. *Brain Pathol*. 2020;30:844-856.
- Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. *Acta Neuropathol*. 2020;139:603-608.
- Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". *Acta Neuropathol*. 2018;136:805-810.
- Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. *Nature*. 2018;555:469-474.
- Müller Bark J, Kulasinghe A, Chua B, Day BW, Punyadeera C. Circulating biomarkers in patients with glioblastoma. *Br J Cancer*. 2020;122:295-305.
- Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. *Nat Rev Clin Oncol*. 2017;14:531-548.
- Mandel P, Metais P. Les acides nucléiques du plasma sanguin chez l'homme. *C R Seances Soc Biol Fil*. 1948;142:241-243.
- Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med*. 2014;6:224ra24.
- Ignatiadis M, Lee M, Jeffrey SS. Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility. *Clin Cancer Res*. 2015;21:4786-4800.
- Baraniskin A, Kuhnhen J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. *Neuro Oncol*. 2012;14:29-33.
- Wolburg H, Noell S, Fallier-Becker P, Mack AF, Wolburg-Buchholz K. The disturbed blood-brain barrier in human glioblastoma. *Mol Aspects Med*. 2012;33:579-589.
- Nassiri F, Chakravarthy A, Feng S, et al. Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. *Nat Med*. 2020;26:1044-1047.
- Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med*. 2011;155:529-536.
- Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. *Nat Cell Biol*. 2008;10:1470-1476.
- Teplyuk NM, Mollenhauer B, Gabriely G, et al. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. *Neuro Oncol*. 2012;14:689-700.
- Ilhan-Mutlu A, Wagner L, Wöhrer A, et al. Blood alterations preceding clinical manifestation of glioblastoma. *Cancer Invest*. 2012;30:625-629.
- Wang Q, Li P, Li A, et al. Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. *J Exp Clin Cancer Res*. 2012;31:97.
- Yang C, Wang C, Chen X, et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. *Int J Cancer*. 2013;132:116-127.
- Akers JC, Ramakrishnan V, Kim R, et al. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. *PLoS One*. 2013;8:e78115.
- Dong L, Li Y, Han C, Wang X, She L, Zhang H. miRNA microarray reveals specific expression in the peripheral blood of glioblastoma patients. *Int J Oncol*. 2014;45:746-756.
- Zhang R, Pang B, Xin T, et al. Plasma miR-221/222 family as novel descriptive and prognostic biomarkers for glioma. *Mol Neurobiol*. 2016;53:1452-1460.
- Manterola L, Guruceaga E, Gállego Pérez-Larraya J, et al. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. *Neuro Oncol*. 2014;16:520-527.
- Zhi F, Shao N, Wang R, et al. Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. *Neuro Oncol*. 2015;17:383-391.
- Lai NS, Wu DG, Fang XG, et al. Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. *Br J Cancer*. 2015;112:1241-1246.
- Sun J, Liao K, Wu X, Huang J, Zhang S, Lu X. Serum microRNA-128 as a biomarker for diagnosis of glioma. *Int J Clin Exp Med*. 2015;8:456-463.
- Wu J, Li L, Jiang C. Identification and evaluation of serum microRNA-29 family for glioma screening. *Mol Neurobiol*. 2015;52:1540-1546.
- Shao N, Wang L, Xue L, Wang R, Lan Q. Plasma miR-454-3p as a potential prognostic indicator in human glioma. *Neurol Sci*. 2015;36:309-313.
- Tang H, Liu Q, Liu X, et al. Plasma miR-185 as a predictive biomarker for prognosis of malignant glioma. *J Cancer Res Ther*. 2015;11:630-634.
- Akers JC, Ramakrishnan V, Kim R, et al. miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. *J Neurooncol*. 2015;123:205-216.
- Shi R, Wang PY, Li XY, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. *Oncotarget*. 2015;6:26971-26981.

36. D'Urso PI, D'Urso OF, Gianfreda CD, Mezzolla V, Storelli C, Marsigliante S. miR-15b and miR-21 as circulating biomarkers for diagnosis of glioma. *Curr Genomics*. 2015;16:304-311.
37. Siegal T, Charbit H, Paldor I, et al. Dynamics of circulating hypoxia-mediated miRNAs and tumor response in patients with high-grade glioma treated with bevacizumab. *J Neurosurg*. 2016;125:1008-1015.
38. Drusco A, Bottoni A, Laganà A, et al. A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. *Oncotarget*. 2015;6:20829-20839.
39. Li HY, Li YM, Li Y, Shi XW, Chen H. Circulating microRNA-137 is a potential biomarker for human glioblastoma. *Eur Rev Med Pharmacol Sci*. 2016;20:3599-3604.
40. Xiao Y, Zhang L, Song Z, et al. Potential diagnostic and prognostic value of plasma circulating microRNA-182 in human glioma. *Med Sci Monit*. 2016;22:855-862.
41. Regazzo G, Terrenato I, Spagnuolo M, et al. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas. *J Exp Clin Cancer Res*. 2016;35:124. <https://doi.org/10.1186/s13046-016-0393-0>
42. Zhao S, Yue S, Yang Q, et al. Serum microRNA-451a expression and its diagnostic value in glioma. *Int J Clin Exp Pathol*. 2016;9:3678-3682.
43. Akers JC, Hua W, Li H, et al. A cerebrospinal fluid microRNA signature as biomarker for glioblastoma. *Oncotarget*. 2017;8:68769-68779.
44. Wei X, Chen D, Lv T, Li G, Qu S. Serum microRNA-125b as a potential biomarker for glioma diagnosis. *Mol Neurobiol*. 2016;53:163-170.
45. Yue X, Lan F, Hu M, Pan Q, Wang Q, Wang J. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. *J Neurosurg*. 2016;124:122-128.
46. Zhao H, Shen J, Hodges TR, Song R, Fuller GN, Heimberger AB. Serum microRNA profiling in patients with glioblastoma: a survival analysis. *Mol Cancer*. 2017;16:59. <https://doi.org/10.1186/s12943-017-0628-5>
47. López-Aguilar JE, Velázquez-Flores MA, Simón-Martínez LA, Ávila-Miranda R, Rodríguez-Flórido MA, Ruiz-Esparza GR. Circulating microRNAs as biomarkers for pediatric astrocytomas. *Arch Med Res*. 2017;48:323-332.
48. Santangelo A, Imbrucè P, Gardenghi B, et al. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. *J Neurooncol*. 2018;136:51-62.
49. Chen J, Yang L, Wang X. Reduced circulating microRNA-203 predicts poor prognosis for glioblastoma. *Cancer Biomark*. 2017;20:521-526.
50. Wang ZQ, Zhang MY, Deng ML, Weng NQ, Wang HY, Wu SX. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma. *PLoS One*. 2017;12:e0184969.
51. Xing W, Zeng C. A novel serum microRNA-based identification and classification biomarker of human glioma. *Tumour Biol*. 2017;39:1010428317705339.
52. Huang Q, Wang C, Hou Z, et al. Serum microRNA-376 family as diagnostic and prognostic markers in human gliomas. *Cancer Biomark*. 2017;19:137-144.
53. Tang Y, Zhao S, Wang J, Li D, Ren Q, Tang Y. Plasma miR-122 as a potential diagnostic and prognostic indicator in human glioma. *Neurol Sci*. 2017;38:1087-1092.
54. Ebrahimkhani S, Vafaei F, Hallal S, et al. Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis. *NPJ Precis Oncol*. 2018;2:28. <https://doi.org/10.1038/s41698-018-0071-0>
55. Kopkova A, Sana J, Machackova T, et al. Cerebrospinal fluid microRNA signatures as diagnostic biomarkers in brain tumors. *Cancers (Basel)*. 2019;11:1546.
56. Zhu M, Zhao W, Zhao H, Zhang J. Diagnostic and prognostic value of microRNA-193b in patients with glioma and its effect on tumor progression. *Oncol Lett*. 2019;18:4882-4890.
57. Yuan F, Liu J, Pang H, et al. MicroRNA-365 suppressed cell proliferation and migration via targeting PAX6 in glioblastoma. *Am J Transl Res*. 2019;11:361-369.
58. Swellam M, Ezz El Arab L, Al-Posttany AS, Said SB. Clinical impact of circulating oncogenic miRNA-221 and miRNA-222 in glioblastoma multiforme. *J Neurooncol*. 2019;144:545-551.
59. Yin J, Zeng A, Zhang Z, Shi Z, Yan W, You Y. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. *EBioMedicine*. 2019;42:238-251.
60. Li J, Yuan J, Yuan XR, et al. Induction effect of MicroRNA-449a on glioma cell proliferation and inhibition on glioma cell apoptosis by promoting PKC α . *Eur Rev Med Pharmacol Sci*. 2015;19:3587-3592.
61. Zhong F, Huang T, Leng J. Serum miR-29b as a novel biomarker for glioblastoma diagnosis and prognosis. *Int J Clin Exp Pathol*. 2019;12:4106-4112.
62. Zhang H, Wang J, Wang Z, Ruan C, Wang L, Guo H. Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients. *Cancer Biomark*. 2019;24:43-49.
63. Wang J, Che F, Zhang J, et al. Diagnostic and prognostic potential of serum cell-free microRNA-214 in glioma. *World Neurosurg*. 2019;125:e1217-e1225.
64. Wang K, Yang S, Gao Y, Zhang C, Sui Q. MicroRNA-769-3p inhibits tumor progression in glioma by suppressing ZEB2 and inhibiting the Wnt/ β -catenin signaling pathway. *Oncol Lett*. 2020;19:992-1000.
65. Ohno M, Matsuzaki J, Kawauchi J, et al. Assessment of the diagnostic utility of serum microRNA classification in patients with diffuse glioma. *JAMA Netw Open*. 2019;2:e1916953.
66. Wang X, Chen X, Sun L, et al. MicroRNA34a inhibits cell growth and migration in human glioma cells via MMP9. *Mol Med Rep*. 2019;20:57-64.
67. Zhang Y, Ta WW, Sun PF, Meng YF, Zhao CZ. Diagnostic and prognostic significance of serum miR-145-5p expression in glioblastoma. *Int J Clin Exp Pathol*. 2019;12:2536-2543.
68. Parviz Hamidi M, Haddad G, Ostadrahimi S, et al. Circulating miR-26a and miR-21 as biomarkers for glioblastoma multiforme. *Biotechnol Appl Biochem*. 2019;66:261-265.
69. Tabibkhouei A, Izadpanahi M, Arab A, et al. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas. *Clin Neurol Neurosurg*. 2020;190:105652.
70. Lan F, Yue X, Xia T. Exosomal microRNA-210 is a potentially non-invasive biomarker for the diagnosis and prognosis of glioma. *Oncol Lett*. 2020;19:1967-1974.
71. Wang LQ, Sun W, Wang Y, Li D, Hu AM. Downregulation of plasma miR-124 expression is a predictive biomarker for prognosis of glioma. *Eur Rev Med Pharmacol Sci*. 2019;23:271-276.
72. Min W, Dai D, Wang J, et al. Long noncoding RNA miR210HG as a potential biomarker for the diagnosis of glioma. *PLoS One*. 2016;11:e0160451.
73. Ma XL, Zhu WD, Tian LX, et al. Long non-coding RNA TUSC7 expression is independently predictive of outcome in glioma. *Eur Rev Med Pharmacol Sci*. 2017;2:3605-3610.
74. Shen J, Hodges TR, Song R, et al. Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. *Mol Carcinog*. 2018;57:137-141.
75. Tan SK, Pastori C, Penas C, et al. Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme. *Mol Cancer*. 2018;17:74-018-0822-0.
76. Hua X, Li G, Liu Z, Niu Z. LINK-A lncRNA participates in the pathogenesis of glioma by interacting with survivin. *Exp Ther Med*. 2019;18:1581-1586.

77. Hu Y, Jiao B, Chen L, Wang M, Han X. Long non-coding RNA GASL1 may inhibit the proliferation of glioma cells by inactivating the TGF- β signaling pathway. *Oncol Lett.* 2019;17:5754-5760.
78. Zhang Z, Yin J, Lu C, Wei Y, Zeng A, You Y. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma. *J Exp Clin Cancer Res.* 2019;38:166-019-1139-6.
79. Chen WW, Balaj L, Liau SML, et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in Glioma patient serum and cerebrospinal fluid extracellular vesicles. *Mol Ther Nucleic Acids.* 2013;2:e109.
80. Reátegui E, van der Vos KE, Lai CP, et al. Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. *Nat Commun.* 2018;9:175.
81. Figueroa JM, Skog J, Akers J, et al. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. *Neuro Oncol.* 2017;19:1494-1502.
82. Balaña C, Ramirez JL, Taron M, et al. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolomide plus cisplatin in glioblastoma multiforme. *Clin Cancer Res.* 2003;9:1461-1468.
83. Weaver KD, Grossman SA, Herman JG. Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. *Cancer Invest.* 2006;24(1):35-40.
84. Wakabayashi T, Natsume A, Hatano H, et al. p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. *Neurosurgery.* 2009;64:455-461.
85. Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. *Neuro Oncol.* 2010;12:173-180.
86. Liu BL, Cheng JX, Zhang W, et al. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. *Neuro Oncol.* 2010;12:540-548.
87. Boisselier B, Gállego Pérez-Larraya J, Rossetto M, et al. Detection of IDH1 mutation in the plasma of patients with glioma. *Neurology.* 2012;76:1693-1698.
88. Shi W, Lv C, Qi J, et al. Prognostic value of free DNA quantification in serum and cerebrospinal fluid in glioma patients. *J Mol Neurosci.* 2012;46:470-475.
89. Majchrzak-Celińska A, Paluszczak J, Kleszcz R, et al. Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. *J Appl Genet.* 2013;54:335.
90. Chen J, Gong M, Lu S, et al. Detection of serum Alu element hypomethylation for the diagnosis and prognosis of glioma. *J Mol Neurosci.* 2013;50:368-375.
91. Salkeni MA, Zazour A, Ansay TY, et al. Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients. *J Neurooncol.* 2013;115:27-35.
92. Fiano V, Trevisan M, Trevisan E, et al. MGMT promoter methylation in plasma of glioma patients receiving temozolomide. *J Neurooncol.* 2014;117:347-357.
93. Wang Z, Jiang W, Wang Y, et al. MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma. *Biomed Rep.* 2015;3:543-548.
94. De Mattos-Arruda L, Mayor R, Ng CKY, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. *Nat Commun.* 2015;6:8839.
95. Wang Y, Springer S, Zhang M. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. *Proc Natl Acad Sci USA.* 2015;112:9704-9709.
96. Chen J, Huan W, Zuo H, et al. Alu methylation serves as a biomarker for non-invasive diagnosis of glioma. *Oncotarget.* 2016;7:26099.
97. Pentsova EI, Shah RH, Tang J. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. *J Clin Oncol.* 2016;34:2404-2415.
98. Panditharatna E, Kilburn LB, Aboian MS, et al. Clinically relevant and minimally invasive tumor surveillance of pediatric diffuse midline gliomas using patient-derived liquid biopsy. *Clin Cancer Res.* 2018;24:5850-5859.
99. Gong M, Shi W, Qi J, et al. Alu hypomethylation and MGMT hypermethylation in serum as biomarkers of glioma. *Oncotarget.* 2017;8:76797-76806.
100. Juratli TA, Stasik S, Zolal Schuster C, et al. A TERT promoter mutation detection in cell-free tumor-derived DNA in patients with IDH wild-type glioblastomas: a Pilot Prospective Study. *Clin Cancer Res.* 2018;24:5282-5291.
101. Moulriere F, Mair R, Chandrananda D, et al. Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients. *EMBO Mol Med.* 2018;10:e9323.
102. Moulriere F, Chandrananda D, Moore PAM, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. *Sci Transl Med.* 2018;10:eaa4921.
103. Martínez-Ricarte F, Mayor R, Martínez-Sáez E, et al. Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumor DNA from cerebrospinal fluid. *Clin Cancer Res.* 2018;24:2812-2819.
104. Miller AM, Shah RH, Pentsova EI, et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. *Nature.* 2019;565:654-658.
105. Piccioni DE, Achrol AS, Kiedrowski LA, et al. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. *CNS Oncol.* 2019;8:CNS34.
106. Bagley SJ, Nabavizadeh SA, Mays JJ, et al. Clinical utility of plasma cell-free DNA in adult patients with newly diagnosed glioblastoma: a Pilot Prospective Study. *Clin Cancer Res.* 2020;26:397-407.
107. Lewis MA, Ganeshan B, Barnes A, et al. Filtration-histogram based magnetic resonance texture analysis (MRTA) for glioma IDH and 1p19q genotyping. *Eur J Radiol.* 2019;113:116-123.
108. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. *Annu Rev Cell Dev Biol.* 2014;30:255-289.
109. Cumba Garcia LM, Peterson TE, Cepeda MA, Johnson AJ, Parney IF. Isolation and analysis of plasma-derived exosomes in patients with glioma. *Front Oncol.* 2019;9:651.
110. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. *Nucleic Acids Res.* 2011;39:7223-7233.
111. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc Natl Acad Sci USA.* 2011;108:5003-5008.
112. Pös O, Biró O, Szemes T, Nagy B. Circulating cell-free nucleic acids: characteristics and applications. *Eur J Hum Genet.* 2018;26:937-945.
113. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. *Oncology.* 1989;46:318-322.
114. Wang J, Bettgowda C. Applications of DNA-based liquid biopsy for central nervous system neoplasms. *J Mol Diagn.* 2017;19:24-34.
115. Lawrie CH. MicroRNAs in hematological malignancies. *Blood Rev.* 2013;27:143-154.
116. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. *Proc Natl Acad Sci USA.* 2008;105:10513-10518.
117. Valihrach L, Androvic P, Kubista M. Circulating miRNA analysis for cancer diagnostics and therapy. *Mol Aspects Med.* 2020;72:100825.
118. Zhu D, Tu M, Zeng B, et al. Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2. *Cancer Med.* 2017;6:452-462.

119. Nabavizadeh SA, Ware JB, Guiry S, et al. Imaging and histopathologic correlates of plasma cell-free DNA concentration and circulating tumor DNA in adult patients with newly diagnosed glioblastoma. *Neurooncol Adv.* 2020;2:vdaa016.
120. García-Romero N, Carrión-Navarro J, Esteban-Rubio S, et al. DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients. *Oncotarget.* 2017;8:1416-1428.
121. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). *Br J Cancer.* 2005;93:387-391.

How to cite this article: Díaz Méndez AB, Tremante E, Regazzo G, Brandner S, Rizzo MG. Time to focus on circulating nucleic acids for diagnosis and monitoring of gliomas: A systematic review of their role as biomarkers. *Neuropathol Appl Neurobiol.* 2021;47:471–487. <https://doi.org/10.1111/nan.12691>

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.